Skip to main content
OpenTrials

Clinical trial condition

Refractory Transformed B-Cell Non-Hodgkin Lymphoma

Explore clinical trials studying Refractory Transformed B-Cell Non-Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.

9 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Refractory Transformed B-Cell Non-Hodgkin Lymphoma trial results

Recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

NCT05077527

Conditions
AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, Blood-Borne Infections, +36 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of Illinois at Chicago Chicago, Illinois, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Montefiore Medical Center - Moses Campus The Bronx, New York, United States
View Trial Details
Recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

NCT06271057

Conditions
Diffuse Large B-cell Lymphoma Refractory, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma, +1 more
Locations
  • Hopital Henri Mondor Créteil, France
  • Chu Dijon Bourgogne Dijon, France
  • Chu de Grenoble La Tronche, France
  • Chru de Lille Lille, France
View all 13 locations
View Trial Details
Recruiting

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

NCT05873712

Conditions
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Non-Hodgkin Lymphoma, +5 more
Locations
  • Icahn School of Medicine at Mount Sinai New York, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • Huntsman Cancer Institute Salt Lake City, Utah, United States
View Trial Details
Completed

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

NCT04703686

Conditions
Diffuse Large B-cell Lymphoma Refractory, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • CHU Amiens Picardie Site sud Amiens, France
  • CHU de Clermont Ferrand Clermont-Ferrand, France
  • Hopital Henri Mondor Créteil, France
  • CHU de Dijon - Hôpital le Bocage Dijon, France
View all 19 locations
View Trial Details
Completed

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

NCT03309878

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
View Trial Details
Active, Not Recruiting

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

NCT05202782

Conditions
Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Hemic and Lymphatic Diseases, +27 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details

Related conditions